Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E14.09 EPS (ttm)7.37 Insider Own0.40% Shs Outstand1.49B Perf Week-0.65%
Market Cap154.64B Forward P/E10.02 EPS next Y10.36 Insider Trans-23.92% Shs Float1.47B Perf Month-0.34%
Income12.10B PEG0.56 EPS next Q2.26 Inst Own85.20% Short Float3.73% Perf Quarter3.52%
Sales24.89B P/S6.21 EPS this Y306.10% Inst Trans-3.34% Short Ratio3.33 Perf Half Y-3.42%
Book/sh10.51 P/B9.88 EPS next Y8.76% ROA58.60% Target Price119.04 Perf Year25.41%
Cash/sh7.87 P/C13.19 EPS next 5Y25.20% ROE122.20% 52W Range63.50 - 116.83 Perf YTD10.15%
Dividend- P/FCF- EPS past 5Y39.10% ROI78.70% 52W High-11.13% Beta0.72
Dividend %- Quick Ratio2.90 Sales past 5Y28.80% Gross Margin84.80% 52W Low63.51% ATR2.29
Employees6100 Current Ratio3.20 Sales Q/Q134.40% Oper. Margin61.30% RSI (14)55.88 Volatility1.39% 2.12%
OptionableYes Debt/Eq0.00 EPS Q/Q373.90% Profit Margin72.30% Rel Volume0.46 Prev Close103.53
ShortableYes LT Debt/Eq0.00 EarningsFeb 03 AMC Payout0.00% Avg Volume16.53M Price103.83
Recom1.80 SMA201.48% SMA502.94% SMA2006.26% Volume7,637,000 Change0.29%
Feb-04-15Reiterated RBC Capital Mkts Outperform $125 → $118
Dec-23-14Reiterated Deutsche Bank Buy $142 → $125
Dec-09-14Reiterated Argus Buy $110 → $130
Oct-29-14Reiterated RBC Capital Mkts Outperform $115 → $125
Oct-13-14Reiterated FBR Capital Outperform $125 → $130
Sep-25-14Reiterated Needham Buy $95 → $120
Aug-22-14Reiterated RBC Capital Mkts Outperform $102 → $115
Aug-15-14Initiated FBR Capital Outperform $125
Aug-11-14Reiterated Argus Buy $90 → $110
Jul-28-14Reiterated Maxim Group Buy $112 → $127
Jul-24-14Reiterated RBC Capital Mkts Outperform $96 → $102
Apr-28-14Reiterated Maxim Group Buy $101 → $112
Feb-21-14Reiterated Barclays Overweight $90 → $95
Feb-10-14Reiterated Argus Buy $84 → $90
Feb-05-14Reiterated RBC Capital Mkts Outperform $90 → $96
Feb-05-14Reiterated Needham Buy $85 → $95
Feb-05-14Reiterated Maxim Group Buy $98 → $101
Feb-04-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
Jan-28-14Reiterated Deutsche Bank Buy $95 → $132
Jan-06-14Reiterated UBS Buy $80 → $102
Mar-02-15 07:01PM  UK cost body backs Gilead's pricey combination hepatitis pill Reuters
05:35PM  Gilead Sciences: The New Market-Share Leader at Investopedia
05:00PM  Gilead Sciences to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3 Business Wire
04:34PM  Gilead's (GILD) HIV Drug Positive in 2 Phase III Studies - Analyst Blog Zacks
02:52PM  Gilead Sciences (GILD), AstraZeneca (AZN), Bellicum Pharmaceuticals (BLCM): Redmile Groups Top New Picks at Insider Monkey
01:27PM  Challenge to a Gilead Sovaldi Patent Continues, Despite New Licensing Deal at The Wall Street Journal
12:37PM  Mallinckrodt PLC (MNK), Pfizer Inc. (PFE): Healthcor Managements Top 5 Health Stocks at Insider Monkey
11:36AM  These are the most profitable Nasdaq biotech companies at MarketWatch
10:48AM  Intercept Pharma (ICPT) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
Feb-27-15 07:08PM  10-K for Gilead Sciences, Inc. Company Spotlight
12:58PM  Gilead Sciences: 'HIV Succession Plan Coming Into Focus' at Barrons.com
12:50PM  ImmunoVaccine Up 24% On Deal With Gilead Sciences Benzinga
12:10PM  Who Might Buy Puma Biotechnology? at Barrons.com
Feb-26-15 07:05PM  Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF) Business Wire
06:51PM  Bristol-Myers: Drug combo cured hepatitis C in 97% with HIV AP
03:55PM  Health Care Stocks Flexing Their Muscle at Forbes
03:45PM  How Gilead Avoids Billions in U.S. Taxes on Its $1,000-a-Pill Drug Bloomberg
03:19PM  Gilead dodges billions in taxes as money rolls in from hepatitis C drugs at San Jose Mercury News
03:15PM  Bristol hep C drug helps cure 97 pct of HIV coinfected patients-study Reuters
03:14PM  Gilead Announces SVR12 Rates From Phase 3 Study Evaluating HarvoniĀ® for the Treatment of Chronic Hepatitis C in Patients Co-Infected With HIV Business Wire
03:05PM  Omega Advisors opens a new position in Gilead Sciences Market Realist
12:51PM  Value hunting in the Nasdaq CNBC
11:10AM  Biotech Making A Comeback - Here Is One Stock to Watch Company Spotlight
11:01AM  Gilead Sciences: Despite Dividend, Still Room For Growth at Barrons.com
09:25AM  Short Sellers Increase Bets Against Biotech as Shares Continue to Rise at 24/7 Wall St.
Feb-25-15 04:11PM  GILEAD SCIENCES INC Files SEC form 10-K, Annual Report EDGAR Online
03:27PM  Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally Suppressed Monkeys Business Wire
10:38AM  Gilead & AbbVie: It Doesn't Matter Which Drug is Better, Just Who Will Pay at Barrons.com
09:56AM  13F Filings Takeaway: Own A Dirty Dozen at Forbes
Feb-24-15 05:00PM  Gilead Sciences to Present at the RBC Capital Markets 2015 Healthcare Conference on Wednesday, February 25 Business Wire
03:39PM  Allergan, Inc. (AGN), HCA Holdings Inc (HCA), Gilead Sciences, Inc. (GILD) Among Healthcare Stocks That Billionaires Love at Insider Monkey
03:15PM  Failure of Anti-HIV Vaginal Gel Shows Difficulty of Prevention at Bloomberg
07:03AM  What's driving the Nasdaq? These 5 stocks CNBC
Feb-23-15 07:58PM  Gilead Sciences, Inc., Amgen, Inc., Biogen Idec Inc Among Billionaires 5 Hottest Biotech Picks at Insider Monkey
04:12PM  How Gilead Sales Have Grown Conspicuously? at Investopedia
11:56AM  Gilead Sciences: Uh Oh, AbbVie Might Be Doing Better Than We Thought at Barrons.com
11:17AM  Biotech on the rise; Analyst likes Gilead CNBC
11:06AM  Big pharma invests big money in research and development Market Realist
08:41AM  Mylan to Distribute Gilead's Hepatitis C Drugs in India at The Wall Street Journal
08:14AM  How Obamacare Pits Insurers Against The Medical Industry at Forbes
Feb-20-15 08:41PM  Overheard: Gilead Needs More Tracks at The Wall Street Journal
03:08PM  Gilead Sciences: How Strong are Hepatitis-C Sales? at Barrons.com
03:07PM  Gilead's One Track Bind at The Wall Street Journal
12:28PM  What it takes to be called big pharma Market Realist
12:00PM  Will Express Scripts (ESRX) Beat Q4 Earnings Estimates? - Analyst Blog Zacks
08:30AM  FDA Fast-Track Should Accrete Significant Value to This Overlooked Biotech Company Spotlight
Feb-19-15 02:54PM  10 Most Popular Healthcare Stocks Among Hedge Funds at Insider Monkey
Feb-18-15 02:08PM  Nasdaq names leading the way CNBC
12:01AM  Gilead's Pill Can Stop HIV. So Why Does Almost Nobody Take It? Bloomberg
Feb-17-15 05:55PM  CVS urges cost controls for new cholesterol drugs Reuters
02:15PM  AbbVie: Amgen Circa 2011? at Barrons.com
11:45AM  Why Gilead Sciences Doesn't Seem Too Worried About AbbVie's Hep-C Treatment at Barrons.com
09:41AM  Apple Inc. (AAPL), Microsoft Corporation (MSFT), and Intel Corporation (INTC): Bridgewater Associates Reveals Top Picks at Insider Monkey
Feb-13-15 04:41PM  Netflix, Amazon Lead Q4 With Biggest Earnings Beat at Investor's Business Daily
10:31AM  Gilead Sciences: Hepatitis-C Tracking at High End of Guidance, RBC Says at Barrons.com
Feb-12-15 01:30PM  AbbVie Seeks Japanese Approval for HCV Cocktail Treatment - Analyst Blog Zacks
10:12AM  The Hepatitis C Scorecard: Gilead is Trouncing AbbVie, but at a Price at The Wall Street Journal
10:07AM  Are Sky-High Prices For New Drugs Justified? at Forbes
09:30AM  The Zacks Analyst Blog Highlights: Achillion Pharmaceuticals, Gilead, AbbVie, Regeneron and Alkermes - Press Releases Zacks
08:54AM  Gilead agrees 41,000 eur hep-C drug price for 12 week treatment Reuters
08:44AM  Brookdale scales up in response to industry dynamics Market Realist
Feb-11-15 04:38PM  Gilead Sciences Shares Rise Amid Insider Buy, Conference Presentation Broadcast - Stocks in the News Zacks
11:47AM  Biotech Stock Roundup: Achillion Impresses with HCV Data, Regeneron 4Q Results Top Estimates - Analyst Blog Zacks
10:19AM  Gilead Sciences: 'Significant Reassurance to Skittish Investors' at Barrons.com
10:03AM  Hey Abbvie, Don't Start What You Can't Finish Yahoo Finance Contributors
07:54AM  JMP Securities Covers Mostly Good News From Pharma Pending More Visibility Benzinga
Feb-10-15 04:38PM  Gilead expects big increase in Europeans treated with hep C drug Reuters
11:10AM  Gilead Faces Sovaldi Patent Challenge in Europe by a Non-Profit Group at The Wall Street Journal
05:00AM  Gilead faces challenge to European patent on pricey hep C drug Reuters
Feb-09-15 05:00PM  Gilead Sciences to Present at Two Upcoming Investor Conferences Business Wire
03:38PM  Achillion Soars on 6 Week HCV Cure When Used with Gilead's Sofosbuvir - Stocks in the News Zacks
03:21PM  [video]Jim Cramer Answers Twitter Questions on Coca-Cola, Yelp, Facebook, and More at TheStreet
12:24PM  Gilead Walloped by Lower Pricing View on Hepatitis C at Barrons.com
Feb-06-15 09:38PM  Gilead's Dividend Debut; GM Relents at Barrons.com
07:04PM  Tech Earnings Soar 17.3%, Largely Thanks To Apple Investor's Business Daily
05:47PM  Can Gilead Boost HCV Sales with Health Service Deals? - Analyst Blog Zacks
05:21PM  Drug price wars 'drive value': Medical exec at CNBC
03:37PM  Gilead Sciences (GILD) Stock Lower Today After Credit Suisse Downgrade at TheStreet
03:23PM  Gilead Sciences, AbbVie and the End of the Hepatitis-C Trade at Barrons.com
03:19PM  Drug price battles CNBC
12:15PM  Credit Suisse Gives Up on Gilead, Sort Of at 24/7 Wall St.
09:34AM  Credit Suisse Downgrades Gilead Sciences, Sees Declining HCV Revenues Benzinga
09:11AM  Morning Movers: Frontier Communications Gains on Verizon Landline Purchase; Gilead Drops on Downgrade at Barrons.com
06:05AM  Biotech Stock Mailbag: Hep C stocks, Bluebird, Advaxis, Hemispherx at TheStreet
Feb-05-15 03:18PM  No, the Gilead-AbbVie Price War Won't Derail the Pharmaceutical Rally at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Biogen, Celgene, AbbVie and Gilead - Press Releases Zacks
07:00AM  Gilead Sciences Inc. (GILD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Zacks
Feb-04-15 07:28PM  Gilead's Harvoni Investor's Business Daily -8.16%
07:28PM  Gilead Investor's Business Daily
06:41PM  Gilead's deep discounts fuel investor worries about drug pricing Reuters
05:46PM  Best biotech plays CNBC
04:44PM  S&P 500 Growth Gets a Boost From A Few Notable Earnings Reports Yahoo Finance Contributors
04:36PM  Midweek Market Recap.. Yahoo Finance Contributors
03:47PM  Gilead Sciences: Look on the Bright Side? at Barrons.com
03:05PM  Competition, discount worries weigh on Gilead shares AP
01:55PM  Gilead to discount its pricey Sovaldi drug at MarketWatch
01:27PM  Gilead sinks on discounting worries at Financial Times
12:49PM  Gilead Down on Discounting News at The Wall Street Journal
12:37PM  Gilead Dislodges a Brick in the Biotech Wall of Worry Yahoo Finance Contributors
12:36PM  Safe biotech plays CNBC
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company', Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Option Exercise16.4070,0001,147,650235,168Feb 19 06:42 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Sale103.0170,0007,210,740165,168Feb 19 06:42 PM
WOLD OLSEN PERDirectorFeb 06Buy99.9210,000999,15088,173Feb 10 04:30 PM
MARTIN JOHN CChairman and CEOFeb 02Option Exercise14.50150,0002,175,3754,272,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Option Exercise25.1433,192834,58683,024Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Option Exercise19.0910,000190,850123,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Option Exercise80.652,000161,30036,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Option Exercise26.995,000134,95020,641Feb 04 04:04 PM
MARTIN JOHN CChairman and CEOFeb 02Sale105.43150,00015,815,2494,122,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Sale105.3833,1923,497,66249,832Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Sale105.7312,0001,268,719111,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Sale106.152,000212,31034,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Sale105.675,000528,35815,641Feb 04 04:04 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Option Exercise16.4070,0001,147,650189,302Jan 20 12:46 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Sale98.4770,0006,893,083119,302Jan 20 12:46 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Option Exercise36.721,00036,72035,308Jan 12 03:55 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Sale100.881,000100,88134,308Jan 12 03:55 PM
MARTIN JOHN CChairman and CEOJan 05Sale96.651009,6654,122,987Jan 06 04:20 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Option Exercise40.561,00040,56035,308Jan 06 04:21 PM
Whitley Richard JamesDirectorJan 02Option Exercise26.995,000134,95020,641Jan 06 02:12 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.095,00095,425120,694Jan 06 04:20 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise14.50150,0002,175,3754,272,987Jan 06 04:20 PM
MARTIN JOHN CChairman and CEOJan 02Sale95.11149,90014,257,7224,123,087Jan 06 04:20 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale95.177,000666,192113,694Jan 06 04:20 PM
Whitley Richard JamesDirectorJan 02Sale95.225,000476,10015,641Jan 06 02:12 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Sale95.051,00095,05034,308Jan 06 04:21 PM
Cogan John FrancisDirectorDec 22Option Exercise14.3426,000372,77568,405Dec 24 12:58 PM
Cogan John FrancisDirectorDec 22Sale95.0326,0002,470,75542,405Dec 24 12:58 PM
MILLIGAN JOHN FPresident and COODec 08Option Exercise8.01146,8231,175,3181,120,871Dec 10 05:32 PM
MILLIGAN JOHN FPresident and COODec 08Sale106.26146,82315,601,122974,048Dec 10 05:32 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise8.01140,6331,125,7674,263,620Dec 03 07:13 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise40.562,00081,12036,308Dec 03 07:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.2931,000752,947149,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Option Exercise26.995,000134,95020,641Dec 03 03:46 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale100.022,000200,03134,308Dec 03 07:14 PM
MARTIN JOHN CChairman and CEODec 01Sale100.72140,63314,164,8294,122,987Dec 03 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale100.7933,0003,325,922116,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Sale100.195,000500,96915,641Dec 03 03:46 PM
Cogan John FrancisDirectorNov 21Option Exercise14.3425,000358,43867,405Nov 25 04:10 PM
Cogan John FrancisDirectorNov 21Sale101.2325,0002,530,77042,405Nov 25 04:10 PM
MILLIGAN JOHN FPresident and COONov 07Option Exercise8.01146,8951,175,8941,120,943Nov 12 12:48 PM
MILLIGAN JOHN FPresident and COONov 07Sale107.37146,89515,772,736974,048Nov 12 12:48 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000055,832Nov 07 01:20 PM
Carter Paul RutherfordEVP Commercial OpsNov 04Option Exercise0.004,800037,044Nov 05 05:37 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Option Exercise40.563,000121,68035,244Nov 05 05:37 PM
Whitley Richard JamesDirectorNov 03Option Exercise26.995,000134,95020,641Nov 05 12:23 PM
MARTIN JOHN CChairman and CEONov 03Option Exercise8.01140,6251,125,7034,570,012Nov 05 02:05 PM
Washington Robin LEVP, CFONov 03Option Exercise25.1433,192834,58683,024Nov 05 08:06 PM
Whitley Richard JamesDirectorNov 03Sale112.025,000560,09015,641Nov 05 12:23 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Sale112.463,000337,38032,244Nov 05 05:37 PM
MARTIN JOHN CChairman and CEONov 03Sale110.40140,62515,525,1024,429,387Nov 05 02:05 PM
Washington Robin LEVP, CFONov 03Sale110.2633,1923,659,83749,832Nov 05 08:06 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Option Exercise40.562,00081,12034,244Oct 28 01:35 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Sale110.002,000220,00732,244Oct 28 01:35 PM
Cogan John FrancisDirectorOct 21Option Exercise14.3415,000215,06357,405Oct 23 01:54 PM
Cogan John FrancisDirectorOct 21Sale104.0815,0001,561,14942,405Oct 23 01:54 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise8.01146,8951,175,8941,120,943Oct 09 02:10 PM
MILLIGAN JOHN FPresident and COOOct 07Sale104.60146,89515,365,818974,048Oct 09 02:10 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise23.7631,000736,405153,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise8.01140,6251,125,7034,570,012Oct 03 02:57 PM
MARTIN JOHN CChairman and CEOOct 01Sale105.91140,62514,893,8454,429,387Oct 03 02:57 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale105.9833,0003,497,259120,694Oct 03 02:53 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Option Exercise40.562,00081,12034,244Sep 30 01:19 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Sale107.472,000214,94532,244Sep 30 01:19 PM
Cogan John FrancisDirectorSep 22Option Exercise14.345,00071,68847,405Sep 24 01:20 PM
Cogan John FrancisDirectorSep 22Sale106.605,000532,98742,405Sep 24 01:20 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise8.01146,8951,175,8941,120,943Sep 10 04:06 PM
MILLIGAN JOHN FPresident and COOSep 08Sale105.99146,89515,569,664974,048Sep 10 04:06 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Option Exercise23.7631,000736,405155,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Option Exercise8.01140,6251,125,7034,570,012Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Option Exercise26.995,000134,95020,641Sep 04 04:31 PM
Whitley Richard JamesDirectorSep 02Sale108.105,000540,50015,641Sep 04 04:31 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Sale108.5833,0003,583,230122,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Sale108.64140,62515,277,9144,429,387Sep 04 05:09 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Option Exercise19.0910,000190,85042,244Aug 28 02:35 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Sale106.1610,0001,061,61832,244Aug 28 02:35 PM
Cogan John FrancisDirectorAug 21Option Exercise14.345,00071,68847,405Aug 25 12:21 PM
Cogan John FrancisDirectorAug 21Sale101.095,000505,44042,405Aug 25 12:21 PM
Washington Robin LEVP, CFOAug 14Option Exercise40.5633,5561,361,03183,388Aug 18 01:10 PM
Washington Robin LEVP, CFOAug 14Sale95.5633,5563,206,61149,832Aug 18 01:10 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Option Exercise26.9916,728451,48948,713Aug 12 04:25 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Sale91.5816,7281,531,88131,985Aug 12 04:25 PM
Washington Robin LEVP, CFOAug 01Option Exercise22.3030,600682,49080,432Aug 05 01:35 PM
Whitley Richard JamesDirectorAug 01Option Exercise26.995,000134,95020,641Aug 05 05:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise0.002,500033,205Aug 05 05:31 PM
MARTIN JOHN CChairman and CEOAug 01Option Exercise8.01140,6251,125,7034,570,012Aug 04 06:16 PM
MARTIN JOHN CChairman and CEOAug 01Sale91.53140,62512,871,8134,429,387Aug 04 06:16 PM
Whitley Richard JamesDirectorAug 01Sale91.005,000455,00015,641Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Sale91.4830,6002,799,34849,832Aug 05 01:35 PM
MOORE NICHOLAS GDirectorJul 28Option Exercise26.6245,0001,197,67545,000Jul 30 12:17 PM
MOORE NICHOLAS GDirectorJul 28Sale90.5645,0004,075,4030Jul 30 12:17 PM
Cogan John FrancisDirectorJul 21Option Exercise14.345,00071,68847,405Jul 23 01:31 PM
Cogan John FrancisDirectorJul 21Sale89.675,000448,34342,405Jul 23 01:31 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Option Exercise26.9916,728451,48947,433Jul 10 01:41 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Sale86.4516,7281,446,07430,705Jul 10 01:41 PM
Whitley Richard JamesDirectorJul 01Option Exercise26.995,000134,95020,641Jul 02 04:24 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise8.01140,6251,125,7034,570,012Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.6131,000731,853159,694Jul 03 03:14 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale84.1233,0002,776,076126,694Jul 03 03:14 PM
MARTIN JOHN CChairman and CEOJul 01Sale84.84140,62511,929,9614,429,387Jul 03 02:28 PM